Wealth Enhancement Advisory Services LLC Has $7.69 Million Stake in Royalty Pharma PLC $RPRX

Wealth Enhancement Advisory Services LLC grew its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 701.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 189,046 shares of the biopharmaceutical company’s stock after buying an additional 165,451 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Royalty Pharma were worth $7,685,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of RPRX. Royal Bank of Canada raised its position in shares of Royalty Pharma by 367.7% in the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after acquiring an additional 160,191 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Royalty Pharma by 20.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock worth $2,490,000 after purchasing an additional 13,489 shares in the last quarter. Focus Partners Wealth acquired a new position in shares of Royalty Pharma in the 1st quarter valued at $264,000. Intech Investment Management LLC grew its holdings in shares of Royalty Pharma by 41.0% in the 1st quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock valued at $1,494,000 after buying an additional 13,951 shares during the period. Finally, American Century Companies Inc. increased its position in shares of Royalty Pharma by 24.0% in the 2nd quarter. American Century Companies Inc. now owns 92,395 shares of the biopharmaceutical company’s stock valued at $3,329,000 after buying an additional 17,894 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Trading Down 1.3%

NASDAQ RPRX opened at $46.35 on Friday. Royalty Pharma PLC has a 52 week low of $29.66 and a 52 week high of $47.86. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.40 and a current ratio of 2.40. The stock’s 50 day moving average price is $44.42 and its two-hundred day moving average price is $40.23. The stock has a market capitalization of $26.74 billion, a price-to-earnings ratio of 34.33 and a beta of 0.40.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.13. The company had revenue of $621.99 million during the quarter, compared to analysts’ expectations of $839.97 million. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. As a group, analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th were paid a dividend of $0.235 per share. The ex-dividend date was Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.0%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio (DPR) is currently 69.63%.

Insider Activity

In other news, CFO Terrance P. Coyne sold 114,954 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the sale, the chief financial officer owned 23,972 shares in the company, valued at $1,026,960.48. This represents a 82.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Marshall Urist sold 20,000 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $39.52, for a total value of $790,400.00. Following the completion of the sale, the executive vice president directly owned 40,000 shares of the company’s stock, valued at approximately $1,580,800. The trade was a 33.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 532,287 shares of company stock valued at $22,215,917 in the last 90 days. 18.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

RPRX has been the topic of several recent analyst reports. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Weiss Ratings upgraded shares of Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, February 12th. Citigroup lifted their price target on shares of Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $48.67.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.